Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ.
Bressler B, et al.
J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058.
J Crohns Colitis. 2021.
PMID: 33786600
Free PMC article.
BACKGROUND AND AIMS: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an alpha4beta7-integrin inhibitor, and anti-tumour necrosis factor-alpha [anti-TNFalpha] agents in biologic-naive ulcerative colitis [UC] and Crohn's disease [CD] patient …
BACKGROUND AND AIMS: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an alpha4beta7-integrin inhibi …